Free Trial

Keros Therapeutics (KROS) Earnings Date, Estimates & Call Transcripts

Keros Therapeutics logo
$61.28 +4.55 (+8.02%)
(As of 12:49 PM ET)

Keros Therapeutics Latest Earnings Summary

Upcoming Q4
Earnings Date
Feb. 26Estimated
Actual EPS
(Nov. 6)
-$1.41 Missed By -$0.13
Consensus EPS
(Nov. 6)
-$1.28

Keros Therapeutics issued Q3 2024 earnings on November 6, 2024, reporting an EPS of -$1.41, which missed analysts' consensus estimates of -$1.28 by $0.13. Quarterly revenue rose 4750.0% year-over-year to $0.39 million. With a trailing EPS of -$5.21, Keros Therapeutics' earnings are expected to decrease next year, from ($5.28) to ($5.76) per share.

KROS Upcoming Earnings

Keros Therapeutics' next earnings date is estimated for Wednesday, February 26, 2025, based off prior year's reporting schedules.

Get Keros Therapeutics Earnings Alerts

Want to stay updated on the latest earnings announcements and upcoming reports? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Keros Therapeutics and other key companies, straight to your inbox.

Sign Up
Skip Charts & View Estimated and Actual Earnings Data

KROS Earnings Estimates and Actuals by Quarter

The chart below shows up to four years of a company's earnings history. The dark blue line represents the company's actual earnings per share. The light blue area represents the range of Wall Street analysts' earnings estimates for each quarter.

KROS Estimated and Actual Revenue by Quarter

The chart below shows up to four years of a company's revenue history. The dark blue line represents the company's actual revenue. The light blue line represents the company's estimated revenue based on the consensus of Wall Street analysts for each quarter.

Keros Therapeutics Analyst EPS Estimates

QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20244-$1.34-$1.22-$1.26
Q2 20244-$1.40-$1.15-$1.24
Q3 20244-$1.47-$1.22-$1.32
Q4 20244-$1.48-$1.30-$1.39
FY 202416-$5.69-$4.89-$5.20
Q1 20253-$1.51-$1.23-$1.39
Q2 20253-$1.57-$1.18-$1.40
Q3 20253-$1.54-$0.98-$1.29
Q4 20253-$1.59-$0.77-$1.24
FY 202512($6.21)($4.16)($5.32)

Keros Therapeutics Earnings History by Quarter

DateQuarterConsensus EstimateReported EPSBeat/MissGAAP EPSRevenue EstimateActual RevenueDetails
2/26/2025
(Estimated)
-------
11/6/2024Q3 2024-$1.28-$1.41 -$0.13-$1.41-$0.39M
8/7/2024Q2 2024-$1.23-$1.25 -$0.02-$1.25-$0.04M
5/8/2024Q1 2024-$1.33-$1.21+$0.12-$1.21-$0.08M
3/1/2024Q4 2023-$1.37-$1.34+$0.03-$1.34-$0.14M
11/6/2023Q3 2023-$1.35-$1.33+$0.02-$1.33-$0.01M
8/7/2023Q2 2023-$1.34-$1.27+$0.07-$1.27$0.22M-
5/4/2023Q1 2023-$1.14-$1.26 -$0.12-$1.26$0.22M-
3/3/2023Q4 2022-$1.12-$1.09+$0.03-$1.09--

Keros Therapeutics Earnings - Frequently Asked Questions

Keros Therapeutics has not confirmed its next earnings publication date, but the company's estimated earnings date is Wednesday, February 26th, 2025 based off last year's report dates. Learn more on KROS's earnings history.

In the previous quarter, Keros Therapeutics (NASDAQ:KROS) missed the analysts' consensus estimate of ($1.28) by $0.13 with a reported earnings per share (EPS) of ($1.41). Learn more on analysts' earnings estimate vs. KROS's actual earnings.

Keros Therapeutics (NASDAQ:KROS) has a recorded annual revenue of $150,000.00.

Keros Therapeutics (NASDAQ:KROS) has a recorded net income of -$152.99 million. KROS has generated -$5.21 earnings per share over the last four quarters.

Keros Therapeutics's earnings are expected to decrease from ($5.28) per share to ($5.76) per share in the next year.

More Earnings Resources from MarketBeat



This page (NASDAQ:KROS) was last updated on 12/3/2024 by MarketBeat.com Staff
From Our Partners